Voronoi, Inc. (310210)
Market Closed
10 Aug, 06:30
KRX SM KRX SM Primary KOSDAQ ₩
176,400. 00
+28,700
+19.4313%
₩
4.15T Market Cap
- P/E Ratio
- Div Yield
164,783 Volume
- Eps
₩ 147,700
Previous Close Want to track 310210 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
310210 closed today higher at ₩176,400, an increase of 19.4313% from yesterday's close, completing a monthly decrease of -6.1702% or -₩11,600. Over the past 12 months, 310210 stock lost -18.3333%.
310210 is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2023, missed the consensus estimates by -395.5171%. On average, the company has fell short of earnings expectations by -395.5171%, based on the last three reports.
Voronoi, Inc. has completed 1 stock splits, with the recent split occurring on Sep 14, 2023.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on KRX SM (KRW).
Voronoi, Inc. (310210) FAQ
What is the stock price today?
The current price is ₩176,400.00.
On which exchange is it traded?
Voronoi, Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 310210.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.15T.
Has Voronoi, Inc. ever had a stock split?
Voronoi, Inc. had 1 splits and the recent split was on Sep 14, 2023.
Voronoi, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Hyuntae Kim CEO | KRX SM Exchange | KR7310210000 ISIN |
| KR Country | 140 Employees | - Last Dividend | 13 Sep 2023 Last Split | - IPO Date |
Overview
Voronoi, Inc. is a South Korean company dedicated to the research, development, and discovery of small molecule kinase inhibitors, focusing on a range of diseases including cancers, autoimmune diseases, pulmonary arterial hypertension, and neurodegenerative disorders. Founded in 2015 and headquartered in Incheon, South Korea, Voronoi has established itself as a key player in the pharmaceutical industry through its innovative approach to treating complex conditions.
Products and Services
- VRN01: An oral leucine rich repeat kinase 2 (LRRK2) inhibitor aimed at treating glioblastoma multiforme, a type of brain cancer, and pancreatic cancer. This product represents Voronoi’s commitment to targeting lethal cancers with precision medicine.
- VRN07, VRN06, and VRN11: A series of compounds specifically designed for the treatment of lung cancer, showcasing Voronoi’s focus on one of the most common and deadly cancer types.
- VRN08 and VRN10: Developed to combat breast cancer, these compounds illustrate the company’s response to a critical global health issue, providing targeted treatment options.
- VRN02: This product is targeted at treating rheumatoid arthritis and atopic dermatitis, demonstrating Voronoi’s expansion into autoimmune and inflammatory diseases.
- VRN04-1: Aimed at treating various autoimmune diseases, this compound signifies the company’s efforts in developing treatments for conditions caused by an overactive immune system.
- VRN04-2: Focused on the treatment of multiple sclerosis and amyotrophic lateral sclerosis, this compound addresses some of the most challenging neurodegenerative diseases, indicating Voronoi’s dedication to advancing neurological health.
- VRN13: Developed for treating pulmonary arterial hypertension, a rare but severe lung disorder, showcasing Voronoi’s initiative in addressing rare diseases with significant unmet medical needs.
- VRN14: Aimed at treating refractory solid cancers, this product targets difficult-to-treat tumors, underscoring the company’s commitment to tackling resistant forms of cancer.
Contact Information
Address: 32, Songdo Gwawak-ro
Phone: 82 3 2219 7838
Website: https://voronoi.io
